Emergent has reportedly had serious problems at Baltimore vaccine plant

Emergent BioSolutions was not prepared to take on the mammoth task of churning out millions of COVID-19 vaccine doses to support U.S. efforts to end the pandemic, according to a report published today in The New York Times.

Emergent was ill-equipped despite a $163 million federal contract to prepare the facility for high-volume production, according to the Times investigation, which relied on previously undisclosed internal documents and interviews with current and former federal officials and former company workers.

Get the full story on our sister site Pharmaceutical Processing World. 

Read more
  • 0

Emergent has reportedly had serious problems at Baltimore vaccine plant

Emergent BioSolutions was not prepared to take on the mammoth task of churning out millions of COVID-19 vaccine doses to support U.S. efforts to end the pandemic, according to a report published today in The New York Times.

Emergent was ill-equipped despite a $163 million federal contract to prepare the facility for high-volume production, according to the Times investigation, which relied on previously undisclosed internal documents and interviews with current and former federal officials and former company workers.

Johnson & Johnson (NYSE:JNJ) this week announced that it will assume full responsibility for the production of its COVID-19 vaccine at the Emergent BioSolutions Bayview (Baltimore) facility — news that came days after the disclosure that a factory error resulted in 15 million discarded COVID-19 vaccines.

The New York Times — citing internal logs, a government official and a former company supervisor — claims that contamination or suspect…

Read more
  • 0

Feds put J&J in charge of vaccine production at Emergent plant

Johnson & Johnson (NYSE:JNJ) announced that it assumed full responsibility for the production of its COVID-19 vaccine at the Emergent BioSolutions Bayview (Baltimore) facility.

The company’s announcement comes days after news broke that a factory error made at that facility resulted in 15 million discarded COVID-19 vaccines.

Get the full story at our sister site, Pharmaceutical Processing World.

Read more
  • 0

Feds put J&J in charge of vaccine production at Emergent plant

Johnson & Johnson (NYSE:JNJ) announced that it assumed full responsibility for the production of its COVID-19 vaccine at the Emergent BioSolutions Bayview (Baltimore) facility.

The company’s announcement comes days after news broke that a factory error made at that facility resulted in 15 million discarded COVID-19 vaccines.

New Brunswick, N.J.-based J&J’s single-dose vaccine was authorized by the FDA  for emergency use in March. Only a handful of days later, the Biden administration announced a contract for 100 million doses of the vaccine.

However, news came to light that, several weeks ago, workers at an Emergent BioSolutions (NYSE:EBS) facility in Baltimore made a mistake several weeks ago when formulating the ingredients for Johnson & Johnson’s COVID-19 vaccine, requiring 15 million doses of it to be discarded.

A quality control process revealed that one batch of a drug substance for the J&J COVID-19 vaccine “did n…

Read more
  • 0

Amid controversy, Biden cancels Emergent Biosolutions visit 

Image from René DeAnda on Unsplash

The White House scrapped plans to hold a Wednesday meeting at a Baltimore-based vaccine plant from Emergent BioSolutions following an exposé from The New York Times.  

The Biden administration also announced plans to conduct an audit of the Strategic National Stockpile after the publication of the article, which described how the biopharmaceutical company lobbied the federal government to buy millions of anthrax vaccine doses. 

Over the past ten years, the U.S. government has devoted almost half of its stockpile budget to BioSolutions’ anthrax vaccine, leaving a dearth of funding for pandemic response. 

Get the full story from our sister site, Pharmaceutical Processing World. 

Read more
  • 0

Amid controversy, Biden cancels Emergent Biosolutions visit 

Image from René DeAnda on Unsplash

The White House scrapped plans to hold a Wednesday meeting at a Baltimore-based vaccine plant from Emergent BioSolutions following an exposé from The New York Times.  

The Biden administration also announced plans to conduct an audit of the Strategic National Stockpile after the publication of the article, which described how the biopharmaceutical company lobbied the federal government to buy millions of anthrax vaccine doses. 

Over the past ten years, the U.S. government has devoted almost half of its stockpile budget to BioSolutions’ anthrax vaccine, leaving a dearth of funding for pandemic response. 

Biden relocated the meeting to the White House, where he will host executives from Merck and Johnson & Johnson, which are jointly manufacturing COVID-19 vaccine. 

“We just felt [the White House] was a more appropriate place to have the meeting,” Jen …

Read more
  • 0